Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07122895) titled 'Sex Differences in NMDA-enhancing Treatment of Schizophrenia' on Aug. 8.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: China Medical University Hospital

Condition: Schizophrenia

Intervention: Drug: NMDAE

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2025

Target Sample Size: 90

Countries of Recruitment: Taiwan

To know more, visit https://clinicaltrials.gov/ct2/show/NCT07122895

Published by HT Dig...